Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2015

01-08-2015 | Retraction Note

Retraction Note to: Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells

Authors: Noriyuki Takai, Tami Ueda, Naoko Kira, Terukazu Ishii, Toshie Yoshida, Satoko Koga, Masakazu Nishida, Kaei Nasu, Hisashi Narahara

Published in: Tumor Biology | Issue 8/2015

Login to get access

Excerpt

Retraction to: Tumor Biol. (2012) 33:1053–1058 …
Metadata
Title
Retraction Note to: Calcium/calmodulin-dependent kinase inhibitor induces growth inhibition, cell cycle arrest, and apoptosis in human choriocarcinoma cells
Authors
Noriyuki Takai
Tami Ueda
Naoko Kira
Terukazu Ishii
Toshie Yoshida
Satoko Koga
Masakazu Nishida
Kaei Nasu
Hisashi Narahara
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3666-x

Other articles of this Issue 8/2015

Tumor Biology 8/2015 Go to the issue

Research Article

Androgen receptor promotes esophageal cancer cell migration and proliferation via matrix metalloproteinase 2

Research Article

The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma

Research Article

C6orf106 enhances NSCLC cell invasion by upregulating vimentin, and downregulating E-cadherin and P120ctn

Review

Mitochondrial targeted peptides for cancer therapy

Research Article

Identification of stage-specific biomarkers in lung adenocarcinoma based on RNA-seq data

Research Commentary

PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits